EANS-Adhoc: Sartorius AG / Preliminary Figures for Fiscal 2009

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

09.02.2010

Consolidated operating earnings up 7.2% | Strong operating cash flow
| Substantial growth and overproportionate earnings increase in the
Biotechnology Division | Slightly positive operating earnings in the
Mechatronics Division due to extensive cost-cutting measures | Growth
in sales revenue and profit expected for both divisions in 2010

In fiscal 2009, the Sartorius Group received orders valued at
615.1 million euros and thus 0.9% (currency-adjusted: -0.4%) more
than in 2008 (609.8 mn. euros). Consolidated sales revenue is at
602.1 million euros, and eased 1.6% (currency-adjusted: -2.7%) from
the year-earlier figure (611.6 mn. euros).

For the Biotechnology Division, order volume climbed 11.5%
(currency-adjusted: +10.3%) to 409.2 million euros from 367.1 million
euros a year ago; sales revenue rose 9.4% (currency-adjusted: +8.3%)
to 400.4 million euros from 366.0 million euros in 2008. By contrast,
the value of the orders posted by the Mechatronics Division slid
15.2% (currency-adjusted: -16.6 %), because of the global recession,
to 205.9 million euros from 242.7 million euros a year earlier; the
division´s sales revenue fell 17.9% (currency-adjusted: -19.3%) to
201.7 million euros from 245.6 million euros a year earlier.

Consolidated earnings before interest, taxes and amortization and
adjusted for extraordinary expenses (underlying EBITA or operating
earnings) rose 7.2% to 60.9 million euros, up from 56.8 million euros
a year ago; the respective margin, from 9.3% to 10.1%. The
Biotechnology Division contributed 60.2 million euros (previous year
39.7 mn. euros) to these earnings, and posted a significant margin
increase from 10.9% to 15.0%. At 0.7 million euros (previous year
17.1 mn. euros), the Mechatronics Division delivered slightly
positive earnings as a result of the restructuring measures
implemented.

Adjusted for extraordinary expenses and excluding the two non-cash
items of amortization and interest, consolidated net profit after
minority interest at 20.8 million euros is 14.2% higher than the
year-earlier figure of 18.2 million euros; the respective earnings
per share rose from 1.07 euros to 1.22 euros. Extraordinary expenses,
which essentially comprise provisions for the restructuring program
in the Mechatronics Division, total 30.0 million euros. In
particular, due to the significant restructuring charges in the
Mechatronics Division the unadjusted consolidated net profit after
minority interest amounts to -7.3 million euros (12.4 mn. euros).

Operating cash flow surged from 53.0 million euros to 143.4 million
euros; the ratio of net debt to underlying EBITDA improved to 2.6 as
of December 31, 2009, from 2.7 a year ago.

For 2010, management expects currency-adjusted sales growth for the
Biotechnology Division to reach the upper single-digit percentage
range and the division´s operating EBITA margin to increase slightly.
For the Mechatronics Division, the company assumes that there will be
a slight upturn in the economy and, on this basis, anticipates
currency-adjusted sales growth in the lower single-digit percentage
range. Given the division´s considerably reduced cost base,
Mechatronics is forecasted to achieve an operating EBITA margin of
around 5%. For the Group as a whole, currency-adjusted sales revenue
growth is likely to be slightly above 5% and its operating EBITA
margin is expected to further improve by one to two percentage
points. Moreover, management anticipates significantly positive
operating cash flow.

The numbers given above are subject to final review by the auditors.
The final figures will be released at the annual press conference on
March 9, 2010.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius,
will discuss the results with analysts and investors on Wednesday,
February 10, 2010, at 4:00 p.m. Central European Time (CET) in a
teleconference. You may dial into the teleconference starting at 3:45
p.m. CET at the following numbers: Germany +49 (0)69 2222 2244;
France +33 (0)1 70 99 42 74; UK +44 (0)20 7136 2053; USA +1 212 444
0481 The dial-in code is: 8415130.

The webcast and presentation can be viewed at www.sartorius.com.

Goettingen, February 9, 2010
-----------------------
Sartorius AG
37070 Göttingen

Andreas Wiederhold

Phone +49(0)551.308.1668
Fax +49(0)551.308.3153
andreas.wiederhold@
sartorius.com
www.sartorius.com

|Ad hoc Announcement |[pic]
|

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Henriette Meyer

Treasury & Investor Relations

Tel.: +49 (0)551-308-3232

E-Mail: henriette.meyer@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade